Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease ...
On Saturday, October 1, during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, Sanofi and Regeneron announced positive data from two Phase 3 clinical trials that support Dupixent (dupilumab) as effective in the treatment of moderate...
Inc.(NASDAQ: REGN) andSanofitoday announced that the second Dupixent®(dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that Dupixent significantly reduced (34%) exacerbations, confirming positiveresultsfrom the landmark Phase 3 B...
The New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® 300 mg weekly experienced significant improvements in signs and symptoms of eo...
Approval for this use in adolescents is supported by evidence from 2 positive, Phase 3 pivotal studies (SINUS-24 and SINUS-52) in adults, as well as pharmacokinetic data from asthma and safety studies in adolescent patients aged 12 years and older. Common side effects for patients with chronic...
2. Efficacy and Safety of Abrocitinib in Patients WithModerate-to-Severe Atopic Dermatitis A Randomized Clinical Trial. 3. Pfizer Presents Positive Phase 3 Data at the 28thCongress of the European Academy of Dermatology and Venereolog...
Paris and Tarrytown, N.Y. October 22, 2023.Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent®(dupilumab) for up to one year (52 weeks) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) was consistent. These results represent ...
Releasing the results of PRIME and PRIME2, phase 3 clinical studies that supported the expanded indication for Dupixent, Ahn said that these studies improve pruritus, nodule clearance, and quality of life in patients with nodular lichen planus. ...
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.< News Galderma gets FDA nod for prurigo nodularis therapy Dermatology specialist Galderma has FDA approval for ...
LIBERTY AD PRESCHOOL is a two-part phase 2/3 trial. The phase 3 randomized, double-blind, placebo-controlled trial (Part B) evaluated the efficacy and safety of Dupixent added to standard-of-care low-potency TCS compared to low-potency TCS alone (placebo) in 162 children aged 6 months to...